Vasoplegia in septic shock: Do we really fight the right enemy?

Journal of Critical Care

Volumn 29, Issue 1, 2014, Pages 83-87

  Sharawy, Nivin ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

H2O2; Sepsis; Shock; Vasoplegia

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANTIOXIDANT; ASCORBIC ACID; CATECHOLAMINE; GLIBENCLAMIDE; HYDROGEN PEROXIDE; METHYLENE BLUE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; REACTIVE OXYGEN METABOLITE; VASOPRESSIN;

BLOOD FLOW; CAPILLARY FLOW; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; HEART OUTPUT; HOMEOSTASIS; HUMAN; INTENSIVE CARE; MICROCIRCULATION; NONHUMAN; OXIDATIVE STRESS; OXYGENATION; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESUSCITATION; REVIEW; SEPTIC SHOCK; SKIN NECROSIS; SMOOTH MUSCLE FIBER; TISSUE PERFUSION; UNSPECIFIED SIDE EFFECT; VASODILATATION; VASOPLEGIA;

H(2)O(2); SEPSIS; SHOCK; VASOPLEGIA;

BIOLOGICAL FACTORS; HUMANS; HYDROGEN PEROXIDE; INTENSIVE CARE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN SPECIES; SHOCK, SEPTIC; VASOPLEGIA;

EID: 84890200494     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2013.08.021     Document Type: Review

References (100)

1. Lundy DJ, Trzeciak S: Microcirculatory dysfunction in sepsis. Crit Care Clin 25:721-731, viii, 2009.
2. Donati A., Conti G., Loggi S., et al. Does methylene blue administration to septic shock patients affect vascular permeability and blood volume?. Crit Care Med 2002, 30:2271-2277.
3. Groeneveld A.B., Bronsveld W., Thijs L.G. Hemodynamic determinants of mortality in human septic shock. Surgery 1986, 99:140-153.
4. Levin M.A., Lin H.M., Castillo J.G., et al. Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation 2009, 120:1664-1671.
5. Shanmugam G. Vasoplegic syndrome-the role of methylene blue. Eur J Cardiothorac Surg 2005, 28:705-710.
6. Matsuda N., Hattori Y. Vascular biology in sepsis: pathophysiological and therapeutic significance of vascular dysfunction. J Smooth Muscle Res 2007, 43:117-137.
7. Boyle E.M., Pohlman T.H., Johnson M.C., et al. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg 1997, 63:277-284.
8. Downing S.W., Edmunds L.H. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 1992, 54:1236-1243.
9. Ignarro L.J. Endothelium-derived nitric oxide: pharmacology and relationship to the actions of organic nitrate esters. Pharm Res 1989, 6:651-659.
10. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43(109-142):14.
11. Pedoto A., Tassiopoulos A.K., Oler A., et al. Treatment of septic shock in rats with nitric oxide synthase inhibitors and inhaled nitric oxide. Crit Care Med 1998, 26:2021-2028.
12. Wright C.E., Rees D.D., Moncada S. Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res 1992, 26:48-57.
13. Szabo C., Wu C.C., Gross S.S., et al. Interleukin-1 contributes to the induction of nitric oxide synthase by endotoxin in vivo. Eur J Pharmacol 1993, 250:157-160.
14. Wu C.C., Szabo C., Chen S.J., et al. Activation of soluble guanylyl cyclase by a factor other than nitric oxide or carbon monoxide contributes to the vascular hyporeactivity to vasoconstrictor agents in the aorta of rats treated with endotoxin. Biochem Biophys Res Commun 1994, 201:436-442.
15. Sade K., Schwartz D., Wolman Y., et al. Time course of lipopolysaccharide-induced nitric oxide synthase mRNA expression in rat glomeruli. J Lab Clin Med 1999, 134:471-477.
16. Harada S., Imaki T., Chikada N., et al. Distinct distribution and time-course changes in neuronal nitric oxide synthase and inducible NOS in the paraventricular nucleus following lipopolysaccharide injection. Brain Res 1999, 821:322-332.
17. Chen K., Inoue M., Okada A. Expression of inducible nitric oxide synthase mRNA in rat digestive tissues after endotoxin and its role in intestinal mucosal injury. Biochem Biophys Res Commun 1996, 224:703-708.
18. Preiser J.C., Zhang H., Vray B., et al. Time course of inducible nitric oxide synthase activity following endotoxin administration in dogs. Nitric Oxide 2001, 5(208-211):15.
19. Kengatharan K.M., De Kimpe S.J., Thiemermann C. Role of nitric oxide in the circulatory failure and organ injury in a rodent model of gram-positive shock. Br J Pharmacol 1996, 119:1411-1421.
20. Strand O.A., Leone A., Giercksky K.E., et al. Nitric oxide indices in human septic shock. Crit Care Med 2000, 28:2779-2785.
21. Scott J.A., Mehta S., Duggan M., et al. Functional inhibition of constitutive nitric oxide synthase in a rat model of sepsis. Am J Respir Crit Care Med 2002, 165:1426-1432.
22. Petros A., Lamb G., Leone A., et al. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994, 28:34-39.
23. Strunk V., Hahnenkamp K., Schneuing M., et al. Selective iNOS inhibition prevents hypotension in septic rats while preserving endothelium-dependent vasodilation. Anesth Analg 2001, 92:681-687.
24. Aksu U., Demirci C., Ince C. The pathogenesis of acute kidney injury and the toxic triangle of oxygen, reactive oxygen species and nitric oxide. Contrib Nephrol 2011, 174:119-128.
25. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000, 87:840-844.
26. Higashi Y., Noma K., Yoshizumi M., et al. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009, 73:411-418.
27. Rabelink T.J., van Zonneveld A.J. Coupling eNOS uncoupling to the innate immune response. Arterioscler Thromb Vasc Biol 2006, 26:2585-2587.
28. Pleiner J., Mittermayer F., Schaller G., et al. High doses of vitamin C reverse Escherichia coli endotoxin-induced hyporeactivity to acetylcholine in the human forearm. Circulation 2002, 106(1460-1464):16.
29. Wort S.J., Evans T.W. The role of the endothelium in modulating vascular control in sepsis and related conditions. Br Med Bull 1999, 55:30-48.
30. Vo P.A., Lad B., Tomlinson J.A., et al. Autoregulatory role of endothelium-derived nitric oxide (NO) on lipopolysaccharide-induced vascular inducible NO synthase expression and function. J Biol Chem 2005, 280:7236-7243.
31. Ince C. The microcirculation is the motor of sepsis. Crit Care 2005, 9(Suppl 4):S13-S19.
32. Tyml K., Li F., Wilson J.X. Septic impairment of capillary blood flow requires nicotinamide adenine dinucleotide phosphate oxidase but not nitric oxide synthase and is rapidly reversed by ascorbate through an endothelial nitric oxide synthase-dependent mechanism. Crit Care Med 2008, 36:2355-2362.
33. Matejovic M., Krouzecky A., Martinkova V., et al. Effects of tempol, a free radical scavenger, on long-term hyperdynamic porcine bacteremia. Crit Care Med 2005, 33:1057-1063.
34. Rossig L., Hoffmann J., Hugel B., et al. Vitamin C inhibits endothelial cell apoptosis in congestive heart failure. Circulation 2001, 104:2182-2187.
35. Heitzer T., Just H., Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996, 94:6-9.
36. Heitzer T., Schlinzig T., Krohn K., et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104:2673-2678.
37. Pleiner J., Mittermayer F., Schaller G., et al. Inflammation-induced vasoconstrictor hyporeactivity is caused by oxidative stress. J Am Coll Cardiol 2003, 42(1656-1662):17.
38. Takakura K., Taniguchi T., Muramatsu I., et al. Modification of alpha1-adrenoceptors by peroxynitrite as a possible mechanism of systemic hypotension in sepsis. Crit Care Med 2002, 30:894-899.
39. Macarthur H., Couri D.M., Wilken G.H., et al. Modulation of serum cytokine levels by a novel superoxide dismutase mimetic, M40401, in an Escherichia coli model of septic shock: correlation with preserved circulating catecholamines. Crit Care Med 2003, 31:237-245.
40. Cauwels A., Rogge E., Janssen B., et al. Reactive oxygen species and small-conductance calcium-dependent potassium channels are key mediators of inflammation-induced hypotension and shock. J Mol Med (Berl) 2010, 88:921-930.
41. Feletou M., Vanhoutte P.M. Endothelium-derived hyperpolarizing factor: where are we now?. Arterioscler Thromb Vasc Biol 2006, 26:1215-1225.
42. Grgic I., Kaistha B.P., Hoyer J., et al. Endothelial Ca+-activated K+ channels in normal and impaired EDHF-dilator responses-relevance to cardiovascular pathologies and drug discovery. Br J Pharmacol 2009, 157:509-526.
43. Clark S.G., Fuchs L.C. Role of nitric oxide and Ca++-dependent K+ channels in mediating heterogeneous microvascular responses to acetylcholine in different vascular beds. J Pharmacol Exp Ther 1997, 282:1473-1479.
44. Vallet B. Endothelial cell dysfunction and abnormal tissue perfusion. Crit Care Med 2002, 30:S229-S234.
45. Ohashi J., Sawada A., Nakajima S., et al. Mechanisms for enhanced endothelium-derived hyperpolarizing factor-mediated responses in microvessels in mice. Circ J 2012, 76(1768-1779):18.
46. Shimokawa H., Yasutake H., Fujii K., et al. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol 1996, 28:703-711.
47. Matoba T., Shimokawa H., Nakashima M., et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest 2000, 106:1521-1530.
48. Rosolowsky M., Campbell W.B. Role of PGI2 and epoxyeicosatrienoic acids in relaxation of bovine coronary arteries to arachidonic acid. Am J Physiol 1993, 264:H327-H335.
49. Edwards G., Dora K.A., Gardener M.J., et al. K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998, 396:269-272.
50. Yamamoto Y., Fukuta H., Nakahira Y., et al. Blockade by 18beta-glycyrrhetinic acid of intercellular electrical coupling in guinea-pig arterioles. J Physiol 1998, 511(Pt 2):501-508.
51. Matoba T., Shimokawa H., Kubota H., et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. Biochem Biophys Res Commun 2002, 290:909-913.
52. Miura H., Bosnjak J.J., Ning G., et al. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ Res 2003, 92:e31-e40.
53. Takaki A., Morikawa K., Tsutsui M., et al. Crucial role of nitric oxide synthases system in endothelium-dependent hyperpolarization in mice. J Exp Med 2008, 205(2053-2063):19.
54. Morikawa K., Fujiki T., Matoba T., et al. Important role of superoxide dismutase in EDHF-mediated responses of human mesenteric arteries. J Cardiovasc Pharmacol 2004, 44:552-556.
55. Cherry P.D., Omar H.A., Farrell K.A., et al. Superoxide anion inhibits cGMP-associated bovine pulmonary arterial relaxation. Am J Physiol 1990, 259:H1056-H1062.
56. Mink S.N., Kasian K., Santos Martinez L.E., et al. Lysozyme, a mediator of sepsis that produces vasodilation by hydrogen peroxide signaling in an arterial preparation. Am J Physiol Heart Circ Physiol 2008, 294:H1724-H1735.
57. Hayabuchi Y., Nakaya Y., Matsuoka S., et al. Hydrogen peroxide-induced vascular relaxation in porcine coronary arteries is mediated by Ca2+-activated K+ channels. Heart Vessels 1998, 13:9-17.
58. Barlow R.S., White R.E. Hydrogen peroxide relaxes porcine coronary arteries by stimulating BKCa channel activity. Am J Physiol 1998, 275:H1283-H1289.
59. Ellis A., Triggle C.R. Endothelium-derived reactive oxygen species: their relationship to endothelium-dependent hyperpolarization and vascular tone. Can J Physiol Pharmacol 2003, 81:1013-1028.
60. Tang X.D., Santarelli L.C., Heinemann S.H., et al. Metabolic regulation of potassium channels. Annu Rev Physiol 2004, 66:131-159.
61. Ardanaz N., Pagano P.J. Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Exp Biol Med (Maywood) 2006, 231:237-251.
62. Suvorava T., Lauer N., Kumpf S., et al. Endogenous vascular hydrogen peroxide regulates arteriolar tension in vivo. Circulation 2005, 112(2487-2495):20.
63. Faraci F.M., Didion S.P. Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol 2004, 24:1367-1373.
64. De Backer D., Donadello K., Taccone F.S., et al. Microcirculatory alterations: potential mechanisms and implications for therapy. Ann Intensive Care 2011, 1:27.
65. De Backer D., Creteur J., Preiser J.C., et al. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 2002, 166:98-104.
66. Dubin A., Pozo M.O., Casabella C.A., et al. Increasing arterial blood pressure with norepinephrine does not improve microcirculatory blood flow: a prospective study. Crit Care 2009, 13:R92.
67. Levy V., Collin S., Sennoun ND., et al. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Med 2010, 36:2019-2029.
68. Russell J.A., Walley K.R., Singer J., et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008, 358:877-887.
69. Annane D., Bellissant E., Cavaillon J.M. Septic shock. Lancet 2005, 365:63-78.
70. Leone M., Boyle W.A. Decreased vasopressin responsiveness in vasodilatory septic shock-like conditions. Crit Care Med 2006, 34:1126-1130.
71. Holmes C.L., Walley K.R., Chittock D.R., et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001, 27:1416-1421.
72. Klinzing S., Simon M., Reinhart K., et al. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003, 31:2646-2650.
73. Dunser M.W., Mayr A.J., Tur A., et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 2003, 31(1394-1398):21.
74. Warrillow S., Egi M., Bellomo R. Randomized, double-blind, placebo-controlled crossover pilot study of a potassium channel blocker in patients with septic shock. Crit Care Med 2006, 34:980-985.
75. Morelli A., Lange M., Ertmer C., et al. Glibenclamide dose response in patients with septic shock: effects on norepinephrine requirements, cardiopulmonary performance, and global oxygen transport. Shock 2007, 28:530-535.
76. Lange M., Morelli A., Westphal M. Inhibition of potassium channels in critical illness. Curr Opin Anaesthesiol 2008, 21:105-110.
77. Andresen M., Dougnac A., Diaz O., et al. Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange. J Crit Care 1998, 13:164-168.
78. Brown G., Frankl D., Phang T. Continuous infusion of methylene blue for septic shock. Postgrad Med J 1996, 72:612-614.
79. Kirov M.Y., Evgenov O.V., Evgenov N.V., et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med 2001, 29:1860-1867.
80. Dumbarton T.C., Minor S., Yeung C.K., et al. Prolonged methylene blue infusion in refractory septic shock: a case report. Can J Anaesth 2011, 58:401-405.
81. Daemen-Gubbels C.R., Groeneveld P.H., Groeneveld A.B., et al. Methylene blue increases myocardial function in septic shock. Crit Care Med 1995, 23:1363-1370.
82. Cauwels A., Buys E.S., Thoonen R., et al. Nitrite protects against morbidity and mortality associated with TNF- or LPS-induced shock in a soluble guanylate cyclase-dependent manner. J Exp Med 2009, 206:2915-2924.
83. Goto M., Zeller W.P., Lichtenberg R.C., et al. Diltiazem treatment of endotoxic shock in suckling rats. J Lab Clin Med 1992, 120(465-470):22.
84. Pastor C.M., Payen D.M. Effect of modifying nitric oxide pathway on liver circulation in a rabbit endotoxin shock model. Shock 1994, 2:196-202.
85. Zhang H., Rogiers P., Friedman G., et al. Effects of nitric oxide donor SIN-1 on oxygen availability and regional blood flow during endotoxic shock. Arch Surg 1996, 131:767-774.
86. Gundersen Y., Corso C.O., Leiderer R., et al. The nitric oxide donor sodium nitroprusside protects against hepatic microcirculatory dysfunction in early endotoxaemia. Intensive Care Med 1998, 24:1257-1263.
87. Spronk P.E., Ince C., Gardien M.J., et al. Nitroglycerin in septic shock after intravascular volume resuscitation. Lancet 2002, 360:1395-1396.
88. Siegemund M., Van Bommel J., Sinaasappel M., et al. The NO donor SIN-1 improves intestinal-arterial P(CO(2)) gap in experimental endotoxemia: an animal study. Acta Anaesthesiol Scand 2007, 51:693-700.
89. Kapadia S., Lee J., Torre-Amione G., et al. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995, 96:1042-1052.
90. Ullrich R., Scherrer-Crosbie M., Bloch K.D., et al. Congenital deficiency of nitric oxide synthase 2 protects against endotoxin-induced myocardial dysfunction in mice. Circulation 2000, 102:1440-1446.
91. Scheibmeir H.D., Christensen K., Whitaker S.H., et al. A review of free radicals and antioxidants for critical care nurses. Intensive Crit Care Nurs 2005, 21:24-28.
92. Cuzzocrea S., Mazzon E., Di Paola R., et al. A role for nitric oxide-mediated peroxynitrite formation in a model of endotoxin-induced shock. J Pharmacol Exp Ther 2006, 319(73-81):23.
93. Lancel S., Tissier S., Mordon S., et al. Peroxynitrite decomposition catalysts prevent myocardial dysfunction and inflammation in endotoxemic rats. J Am Coll Cardiol 2004, 43:2348-2358.
94. Zingarelli B., Day B.J., Crapo J.D., et al. The potential role of peroxynitrite in the vascular contractile and cellular energetic failure in endotoxic shock. Br J Pharmacol 1997, 120:259-267.
95. Cuzzocrea S., Costantino G., Mazzon E., et al. Beneficial effects of Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP), a superoxide dismutase mimetic, in zymosan-induced shock. Br J Pharmacol 1999, 128:1241-1251.
96. Ohya M., Marukawa S., Inoue T., et al. Plasma nitrotyrosine concentration relates to prognosis in human septic shock. Shock 2002, 18:116-118.
97. He X., Su F., Velissaris D., et al. Administration of tetrahydrobiopterin improves the microcirculation and outcome in an ovine model of septic shock. Crit Care Med 2012, 40:2833-2840.
98. Fitzal F., Redl H., Strohmaier W., et al. A 4-amino analogue of tetrahydrobiopterin attenuates endotoxin-induced hemodynamic alterations and organ injury in rats. Shock 2002, 18:158-162.
99. Bahrami S., Fitzal F., Peichl G., et al. Protection against endotoxemia in rats by a novel tetrahydrobiopterin analogue. Shock 2000, 13:386-391.
100. Mittermayer F., Pleiner J., Schaller G., et al. Tetrahydrobiopterin corrects Escherichia coli endotoxin-induced endothelial dysfunction. Am J Physiol Heart Circ Physiol 2005, 289:H1752-H1757.